Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Mais filtros











Base de dados
Intervalo de ano de publicação
1.
Appl Radiat Isot ; 106: 260-4, 2015 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-26515137

RESUMO

In the frame of the Argentine BNCT Project a new research line has been started to study the application of BNCT to the treatment of locoregional recurrences of HER2+ breast cancer subtype. Based on former studies, the strategy considers the use of immunoliposomes as boron carriers nanovehicles to target HER2 overexpressing cells. The essential concerns of the current stage of this proposal are the development of carriers that can improve the efficiency of delivery of boron compounds and the dosimetric assessment of treatment feasibility. For this purpose, an specific pool of clinical cases that can benefit from this application was determined. In this work, we present the proposal and the advances related to the different stages of current research.

2.
Appl Radiat Isot ; 104: 155-9, 2015 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-26164147

RESUMO

In the frame of the Argentine BNCT Project a new research line has been started to study the application of BNCT to the treatment of locoregional recurrences of HER2+ breast cancer subtype. Based on former studies, the strategy considers the use of immunoliposomes as boron carriers nanovehicles to target HER2 overexpressing cells. The essential concerns of the current stage of this proposal are the development of carriers that can improve the efficiency of delivery of boron compounds and the dosimetric assessment of treatment feasibility. For this purpose, an specific pool of clinical cases that can benefit from this application was determined. In this work, we present the proposal and the advances related to the different stages of current research.


Assuntos
Pesquisa Biomédica/tendências , Terapia por Captura de Nêutron de Boro/tendências , Neoplasias da Mama/radioterapia , Oncologia/tendências , Recidiva Local de Neoplasia/radioterapia , Argentina , Neoplasias da Mama/metabolismo , Feminino , Humanos , Recidiva Local de Neoplasia/metabolismo , Recidiva Local de Neoplasia/prevenção & controle , Receptor ErbB-2/metabolismo , Resultado do Tratamento
3.
Appl Radiat Isot ; 67(7-8 Suppl): S206-9, 2009 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-19394239

RESUMO

As a part of the project concerning the irradiation of a section of the human liver left lobe, a preliminary estimation of the expected dose was performed. To obtain proper input values for the calculation, neutron flux and gamma dose rate characterization were carried out using adequate portions of cow or pig liver covered with demineralized water simulating the preservation solution. Irradiations were done inside a container specially designed to fulfill temperature preservation of the organ and a reproducible irradiation position (which will be of importance for future planification purposes). Implantable rhodium based self-powered neutron detectors were developed to obtain neutron flux profiles both external and internal. Implantation of SPND was done along the central longitudinal axis of the samples, where lowest flux is expected. Gamma dose rate was obtained using a neutron shielded graphite ionization chamber moved along external surfaces of the samples. The internal neutron profile resulted uniform enough to allow for a single and static irradiation of the liver. For dose estimation, irradiation condition was set in order to obtain a maximum of 15 Gy-eq in healthy tissue. Additionally, literature reported boron concentrations of 47 ppm in tumor and 8 ppm in healthy tissue and a more conservative relationship (30/10 ppm) were used. To make a conservative estimation of the dose the following considerations were done: i). Minimum measured neutron flux inside the sample (approximately 5 x 10(9) n cm-2 s-1) was considered to calculate dose in tumor. (ii). Maximum measured neutron flux (considering both internal as external profiles) was used to calculate dose in healthy tissue (approximately 8.7 x 10(9) n cm-2 s-1). (iii). Maximum measured gamma dose rate (approximately 13.5 Gy h-1) was considered for both tumor and healthy tissue. Tumor tissue dose was approximately 69 Gy-eq for 47 ppm of (10)B and approximately 42 Gy-eq for 30 ppm, for a maximum dose of 15 Gy-eq in healthy tissue. As can be seen from these results, even for the most conservative case, minimum tumor dose will be acceptable from the treatment point of view, which shows that the irradiation conditions at this facility have quite good characteristics for the proposed irradiation.


Assuntos
Terapia por Captura de Nêutron de Boro/instrumentação , Neoplasias Hepáticas/radioterapia , Radiometria/instrumentação , Radiometria/estatística & dados numéricos , Planejamento da Radioterapia Assistida por Computador/estatística & dados numéricos , Animais , Argentina , Terapia por Captura de Nêutron de Boro/estatística & dados numéricos , Nêutrons Rápidos/uso terapêutico , Raios gama/uso terapêutico , Humanos , Técnicas In Vitro , Neoplasias Hepáticas/secundário , Neoplasias Hepáticas/cirurgia , Transplante de Fígado , Reatores Nucleares , Suínos , Transplante Autólogo
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA